[Translation] A phase Ia clinical study to evaluate the safety, tolerability and pharmacokinetics of a single dose of Bungarus antimicrobial peptide vaginal effervescent tablets in healthy adult female subjects: a randomized, double-blind, placebo-controlled parallel study

主要目的：评价健康成年女性受试者单次给药金环蛇抗菌肽阴道泡腾片的安全性和耐受性。次要目的：评价健康成年女性受试者单次给药金环蛇抗菌肽阴道泡腾片的初步人体药代动力学特征。

[Translation]

Primary objective: To evaluate the safety and tolerability of a single dose of Bungarus antimicrobial peptide vaginal effervescent tablets in healthy adult female subjects. Secondary objective: To evaluate the preliminary human pharmacokinetic characteristics of a single dose of Bungarus antimicrobial peptide vaginal effervescent tablets in healthy adult female subjects.

Start Date03 Nov 2021

Sponsor / Collaborator

Suzhou Kanger Biomedical Co. Ltd.

[+1]

100 Clinical Results associated with Cathelicidin-BF

100 Translational Medicine associated with Cathelicidin-BF

100 Patents (Medical) associated with Cathelicidin-BF

233

Literatures (Medical) associated with Cathelicidin-BF

01 Dec 2024·Current Protein & Peptide Science

Evaluation of Novel HLM Peptide Activity and Toxicity against Planktonic and Biofilm Bacteria: Comparison to Standard Antibiotics

Article

Author: Sabi, Salsabeel H. ; Masadeh, Majd M. ; Almomani, Enaam ; Alsaggar, Mohammad ; Massadeh, Majd M ; Alzoubi, Karem H ; Masadeh, Majed M. ; Masadeh, Majed M ; Sabi, Salsabeel ; Alrabadi, Nasr ; Alshogran, Haneen ; Al Momany, Enaam M. ; Alzoubi, Karem H.

Background:Antibiotic resistance is one of the main concerns of public health, and the whole world is trying to overcome such a challenge by finding novel therapeutic modalities and approaches. This study has applied the sequence hybridization approach to the original sequence of two cathelicidin natural parent peptides (BMAP-28 and LL-37) to design a novel HLM peptide with broad antimicrobial activity.Methods:The physicochemical characteristics of the newly designed peptide were determined. As well, the new peptide’s antimicrobial activity (Minimum Inhibitory Concentration (MIC), Minimum Bacterial Eradication Concentration (MBEC), and antibiofilm activity) was tested on two control (Staphylococcus aureus ATCC 29213, Escherichia coli ATCC 25922) and two resistant (Methicillin-resistant Staphylococcus aureus (MRSA) ATCC BAA41, New Delhi metallo-beta- lactamase-1 Escherichia coli ATCC BAA-2452) bacterial strains. Furthermore, synergistic studies have been applied to HLM-hybridized peptides with five conventional antibiotics by checkerboard assays. Also, the toxicity of HLM-hybridized peptide was studied on Vero cell lines to obtain the IC50 value. Besides the percentage of hemolysis action, the peptide was tested in freshly heparinized blood.Results:The MIC values for the HLM peptide were obtained as 20, 10, 20, and 20 μM, respectively. Also, the results showed no hemolysis action, with low to slightly moderate toxicity action against mammalian cells, with an IC50 value of 10.06. The Biomatik corporate labs, where HLM was manufactured, determined the stability results of the product by Mass Spectrophotometry (MS) and High-performance Liquid Chromatography (HPLC) methods. The HLM-hybridized peptide exhibited a range of synergistic to additive antimicrobial activities upon combination with five commercially available different antibiotics. It has demonstrated the biofilm-killing effects in the same concentration required to eradicate the control strains.Conclusion:The results indicated that HLM-hybridized peptide displayed a broad-spectrum activity toward different bacterial strains in planktonic and biofilm forms. It showed synergistic or additive antimicrobial activity upon combining with commercially available different antibiotics.

01 Oct 2024·Journal of Leukocyte Biology

The role of cathelicidins in neutrophil biology

Review

Author: Multani, Anmol ; Puentes, Rodrigo ; Yoon, Grace ; Tran, Jacquelyn ; Cobo, Eduardo R

AbstractDespite their relatively short lifespan, neutrophils are tasked with counteracting pathogens through various functions, including phagocytosis, production of reactive oxygen species, neutrophil extracellular traps (NETs), and host defense peptides. Regarding the latter, small cationic cathelicidins present a conundrum in neutrophil function. Although primarily recognized as microbicides with an ability to provoke pores in microbial cell walls, the ability of cathelicidin to modulate key neutrophil functions is also of great importance, including the release of chemoattractants, cytokines, and reactive oxygen species, plus prolonging neutrophil lifespan. Cumulative evidence indicates a less recognized role of cathelicidin as an “immunomodulator”; however, this term is not always explicit, and its relevance in neutrophil responses during infection and inflammation is seldom discussed. This review compiles and discusses studies of how neutrophils use cathelicidin to respond to infections, while also acknowledging immunomodulatory aspects of cathelicidin through potential crosstalk between sources of the peptide.

30 Jul 2024·Open Life Sciences

Evaluation of the activity of antimicrobial peptides against bacterial vaginosis

Article

Author: Han, Qinqin ; Yuan, Tao ; Kang, Xuning ; Zhang, Jinyang ; Song, Yuzhu ; Zhao, Ting

AbstractNew drugs for the treatment of bacterial vaginosis (BV) are yet to be developed due to concerns that they may contribute to the increase in antibiotic resistance in BV. Antimicrobial peptides (AMPs) are one of the most promising options for next-generation antibiotics. In this study, we investigated the bacteriostatic activity of the AMPs Pexiganan, plectasin, melittin, and cathelicidin-DM against Gram-negative and Gram-positive bacteria both in vitro and in a mouse model of BV infection. The results showed that Pexiganan, melittin, and cathelicidin-DM had significant antibacterial activity against both Gram-negative and Gram-positive bacteria. AMPs have great potential for clinical application in the treatment of vaginitis, and this study provides an experimental basis for their use in the active immunoprophylaxis of BV.

100 Deals associated with Cathelicidin-BF

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bacterial Vaginosis	Phase 1	CN	Suzhou Kanger Biomedical Co. Ltd.	03 Nov 2021
Bacterial Vaginosis	Phase 1	CN	China Pharmaceutical University	03 Nov 2021
Gram-Negative Bacterial Infections	Preclinical	CN	Chinese Academy of Sciences	16 Sep 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Cathelicidin-BF

Overview

Basic Info

Gene Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation